UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | October 29, 2015 |
Cytokinetics, Incorporated
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 000-50633 | 94-3291317 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 280 East Grand Avenue, South San Francisco, California | 94080 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | (650) 624 - 3000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2015, Cytokinetics, Incorporated issued a press release announcing its results for the third quarter ended September 30, 2015. A copy of the press release is being filed as Exhibit 99.1 to this Current Report and is hereby incorporated by reference into this item 2.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following Exhibits are filed as part of this Current Report on Form 8-K:
Exhibit No. Description
----------------------------------
99.1 Press Release, dated October 29, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cytokinetics, Incorporated | ||||
| October 29, 2015 | By: |
/s/ Sharon Barbari
|
||
|
|
||||
| Name: Sharon Barbari | ||||
| Title: Executive Vice President, Finance and Chief Financial Officer | ||||
Exhibit Index
| Exhibit No. | Description | |
|
|
|
|
|
99.1
|
Press Release, dated October 29, 2015 |
CYTOKINETICS, INC. REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS
Recently Announced Positive Top-line Results From COSMIC-HF; Data Demonstrated Statistically
Significant Improvements in Several Pre-Specified Measures of Cardiac Function
Company Lowers 2015 R&D Expense Guidance
SOUTH SAN FRANCISCO, CA, October 29, 2015 - Cytokinetics, Inc. (Nasdaq: CYTK) reported total research and development revenues for the third quarter of 2015 were $7.9 million, compared to $9.4 million during the same period in 2014. The net loss for the third quarter was $8.8 million, or $0.23 per basic and diluted share. This is compared to a net loss for the same period in 2014 of $6.0 million, or $0.16 per basic share and diluted share. As of September 30, 2015, cash, cash equivalents and investments totaled $98.0 million.
“With the recently announced positive results from COSMIC-HF, Cytokinetics has entered a transformative time in the maturation of our company. We look forward to working with our partners at Amgen to prepare for potential progression of omecamtiv mecarbil to Phase 3,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “During the quarter, we achieved another key milestone for the company with the start of our first Phase 3 clinical trial of tirasemtiv in patients with ALS and prepared to advance CK-2127107 into a Phase 2 clinical trial in patients with SMA, in collaboration with Astellas. This is truly an exciting time for our company and our key stakeholders.”
Recent Highlights and Upcoming Milestones
Skeletal Muscle Program
tirasemtiv
Initiated enrollment in VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), a Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity (SVC) and other measures of skeletal muscle strength in patients with ALS.
Achieved first milestone in accordance with a $1.5M grant from The ALS Association to support VITALITY-ALS and the collection of plasma samples to advance the discovery of biomarkers for ALS.
CK-2127107
Continued planning for the initiation of a Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), in collaboration with Astellas, to occur in the fourth quarter of 2015.
Anticipate Astellas will initiate a Phase 2 clinical trial of CK-2127107 in patients with COPD in the first half of 2016.
Cardiac Muscle Program
omecamtiv mecarbil
Recently announced positive results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) which demonstrated statistically significant improvements in several pre-specified echocardiographic measures of cardiac function, including systolic ejection time, stroke volume and N-terminal-pro-brain natriuretic peptide, at 20 weeks following randomization. These pharmacodynamic effects of omecamtiv mecarbil were generally dose dependent. Data from the expansion phase of COSMIC-HF showed that pharmacokinetic-guided dose titration adequately controlled patient exposure to omecamtiv mecarbil and resulted in statistically significant decreases in cardiac dimensions and heart rate in the dose-titration group. Adverse events, including serious adverse events, in patients on omecamtiv mecarbil, appeared comparable to those on placebo. COSMIC-HF was conducted by Amgen in collaboration with Cytokinetics.
Conducted planning in collaboration with Amgen, for the potential advancement of omecamtiv mecarbil into a Phase 3 program.
Pre-Clinical Research
Continued research activities under our joint research program with Amgen directed to the discovery of next-generation cardiac muscle activators and under our joint research program with Astellas directed to the discovery of next-generation skeletal muscle activators. In addition, company scientists continued independent research activities directed to our other muscle biology programs.
Corporate
Established a $40 million Controlled Equity Offering line with Cantor Fitzgerald.
Entered into a $40 million tranched growth capital loan with Oxford Financial LLC and Silicon Valley Bank, with the first tranche of $15 million funded in October 2015.
Participated in several events associated with Gold Level Sponsorship of the National Walks to Defeat ALS and Platinum Level Sponsorship of the ALS Association Golden West Chapter.
Financials
Revenues for the third quarter of 2015 were $7.9 million, compared to $9.4 million during the same period in 2014. Revenues for the third quarter of 2015 included $4.1 million of license revenues and $3.2 million of research and development revenues from our collaboration with Astellas, and $0.6 million in research and development revenues from our collaboration with Amgen. Revenues for the same period in 2014 were comprised of $2.7 million of license revenues and $4.8 million of research and development revenues from our collaboration with Astellas, and $1.9 million of research and development revenues from our collaboration with Amgen.
Total research and development (R&D) expenses for the third quarter of 2015 were $11.6 million, compared to $11.4 million for the same period in 2014. The $0.2 million increase in R&D expenses for the third quarter of 2015, compared with the same period in 2014, was primarily due to an increase of $0.6 million in outsourced preclinical costs and lab expenses and an increase of $0.6 million in personnel related expenses, partially offset by a decrease of $1.0 million in outsourced clinical costs associated with the completion of BENEFIT-ALS in the second quarter of 2014.
Total general and administrative (G&A) expenses for the third quarter of 2015 were $5.3 million compared to $4.0 million for the same period in 2014. The $1.3 million increase in G&A expenses for the third quarter of 2015, compared to the same period in 2014, was primarily due to an increase of $0.7 million in outsourced costs, $0.4 million in legal fees, and $0.2 million in personnel related expenses due to an increase in headcount.
Revenues for the nine months ended September 30, 2015 were $18.9 million, compared to $25.2 million for the same period in 2014. Revenues for the first nine months of 2015 included $8.8 million of license revenues and $8.2 million of research and development revenues from our collaboration with Astellas, and $1.9 million of research and development revenues from our collaboration with Amgen. Revenues for the same period in 2014 were comprised of $7.6 million of license revenues and $14.1 million of research and development revenues from our collaboration with Astellas, and $3.4 million of research and development revenues from our collaboration with Amgen.
Total R&D expenses for the nine months ended September 30, 2015 were $33.1 million, compared to $35.6 million for the same period in 2014. The $2.5 million decrease in R&D expenses in the first nine months of 2015, over the same period in 2014, was primarily due to a decrease of $5.0 million in outsourced clinical costs associated with the completion of BENEFIT-ALS in the second quarter of 2014, partially offset by an increase of $0.8 million in outsourced preclinical costs, an increase of $0.6 million in lab expenses, and an increase of $1.0 million in personnel related expenses due to increased headcount.
Total G&A expenses for the nine months ended September 30, 2015 were $14.1 million, compared to $12.7 million for the same period in 2014. The $1.4 million increase in G&A spending in the first nine months of 2015 compared to the same period in 2014, was primarily due to an increase of $0.8 million in personnel related costs due to an increase in headcount, an increase of $0.6 in legal fees, and an increase of $0.1 million in outsourced costs.
The net loss for the nine months ended September 30, 2015, was $28.3 million, or $0.73 per basic and diluted share, compared to a net loss of $23.1 million, or $0.65 per basic and diluted share, for the same period in 2014.
Financial Guidance
Cytokinetics also announced updated financial guidance for 2015. The company anticipates cash revenue will be in the range of $44 to $47 million, cash R&D expenses will be in the range of $51 to $54 million, and cash G&A expenses will be in the range of $18 to $21 million. This guidance includes approximately $30.0 million in revenue which will be deferred and recognized over a two year period ending in 2016 under generally accepted accounting principles. This guidance excludes an estimated $4.6 million in non-cash related operating expenses primarily related to stock compensation expense.
Conference Call and Webcast Information
Members of Cytokinetics’ senior management team will review the company’s third quarter results via a webcast and conference call today at 4:30 PM Eastern Time. The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 34469080.
An archived replay of the webcast will be available via Cytokinetics’ website until November 5, 2015. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 34469080 from October 29, 2015 at 5:30 PM Eastern Time until November 5, 2015.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics’ specified development and commercialization participation rights. For additional information about Cytokinetics, visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities, including expected revenue and R&D and G&A expenses, the initiation, conduct, design, enrollment, progress, continuation, completion and results of clinical trials, the significance and utility of preclinical study and clinical trial results, the expected availability of clinical trial results, planned interactions with regulatory authorities and the outcomes of such interactions; enrollment in VITALITY-ALS; the potential progression of CK-2127107 to Phase II development, the potential progression of omecamtiv mecarbil to Phase III development; potential milestone payments; the expected timing of events; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to further clinical development of tirasemtiv in ALS patients which will require significant additional funding, and Cytokinetics may be unable to obtain such additional funding on acceptable terms, if at all; the FDA and/or other regulatory authorities may not accept effects on slow vital capacity as a clinical endpoint to support registration of tirasemtiv for the treatment of ALS; additional Phase I clinical trials for CK-2127107 may be required; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Amgen’s and Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil and CK-2127107, respectively; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; Cytokinetics may be unable to enter into future collaboration agreements for its drug candidates and programs on acceptable terms, if at all; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3000
Cytokinetics, Incorporated
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||||||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||||||||||||||||||
Revenues: |
||||||||||||||||||||||||||||||||
Research and development revenues from |
||||||||||||||||||||||||||||||||
related parties |
$ | 3,786 | $ | 1,920 | $ | 10,087 | $ | 3,428 | ||||||||||||||||||||||||
Research and development, grant and other |
||||||||||||||||||||||||||||||||
revenues |
27 | 4,761 | 27 | 14,189 | ||||||||||||||||||||||||||||
License revenues from related parties |
4,132 | — | 8,787 | — | ||||||||||||||||||||||||||||
License revenues |
— | 2,734 | — | 7,565 | ||||||||||||||||||||||||||||
Total revenues |
7,945 | 9,415 | 18,901 | 25,182 | ||||||||||||||||||||||||||||
Operating Expenses: |
||||||||||||||||||||||||||||||||
Research and development |
11,557 | 11,420 | 33,149 | 35,647 | ||||||||||||||||||||||||||||
General and administrative |
5,276 | 3,993 | 14,138 | 12,710 | ||||||||||||||||||||||||||||
Total operating expenses |
16,833 | 15,413 | 47,287 | 48,357 | ||||||||||||||||||||||||||||
Operating loss |
(8,888 | ) | (5,998 | ) | (28,386 | ) | (23,175 | ) | ||||||||||||||||||||||||
Interest and other, net |
39 | 27 | 114 | 86 | ||||||||||||||||||||||||||||
Net loss |
$ | (8,849 | ) | $ | (5,971 | ) | $ | (28,272 | ) | $ | (23,089 | ) | ||||||||||||||||||||
Net loss per share – basic and diluted |
$ | (0.23 | ) | $ | (0.16 | ) | $ | (0.73 | ) | $ | (0.65 | ) | ||||||||||||||||||||
Weighted average shares used in computing net
loss per share – basic and diluted |
38,752 | 36,609 | 38,718 | 35,359 | ||||||||||||||||||||||||||||
Cytokinetics, Incorporated
Condensed Consolidated Balance Sheets
(in thousands)
| September 30, | December 31, | |||||||
| 2015 | 2014(1) | |||||||
| (unaudited) | ||||||||
Assets |
||||||||
Cash and cash equivalents |
$ | 25,962 | $ | 20,215 | ||||
Short term investments |
72,023 | 63,013 | ||||||
Accounts receivable and related party receivable |
47 | 46,646 | ||||||
Other current assets |
2,483 | 1,257 | ||||||
Total current assets |
100,515 | 131,131 | ||||||
Property and equipment, net |
1,481 | 1,637 | ||||||
Other assets |
200 | 200 | ||||||
Total assets |
$ | 102,196 | $ | 132,968 | ||||
Liabilities and stockholders’ equity |
||||||||
Deferred revenue, current |
$ | 21,367 | $ | 17,042 | ||||
Other current liabilities |
8,776 | 6,813 | ||||||
Total current liabilities |
30,143 | 23,855 | ||||||
Deferred revenue, non-current |
4,346 | 16,558 | ||||||
Other non-current liabilities |
407 | 491 | ||||||
Stockholders’ equity |
67,300 | 92,064 | ||||||
Total liabilities and stockholders’ equity |
$ | 102,196 | $ | 132,968 | ||||
(1) Derived from the audited financial statements, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.